CHRONIC GRAFT VS. HOST DISEASE

Clinical trials for CHRONIC GRAFT VS. HOST DISEASE explained in plain language.

Never miss a new study

Get alerted when new CHRONIC GRAFT VS. HOST DISEASE trials appear

Sign up with your email to follow new studies for CHRONIC GRAFT VS. HOST DISEASE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 3 Not yet finished but already full! 1

New hope for transplant patients with devastating lung damage

Disease control Ongoing

This early-stage study is testing an oral drug called alvelestat for people who develop a serious lung scarring condition (BOS) after a stem cell transplant. The goal is to find a safe dose that blocks a harmful enzyme thought to cause the lung damage and to see if that dose can …

Matched conditions: CHRONIC GRAFT VS. HOST DISEASE

Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control

Last updated Mar 11, 2026 14:53 UTC

CHRONIC GRAFT VS. HOST DISEASE

Get alerted when new CHRONIC GRAFT VS. HOST DISEASE trials appear

New hope for transplant patients with devastating lung damage